This may warrant clinical trials of D2 dopamine receptor agonists since pramipexole and pergolide show efficacy in reducing depression in patients with PD [37, 38], as well as symptoms of major depression in patients without PD [39, 40]. Here, DRD2 is linked to Parkinson disease.